glp-1 and mash The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis GLP-1 therapies: a new frontier

A 17-year-old female with a history of epilepsy on carbamazepine, zonisamide, and levetiracetam is hospitalized for breakthrough seizures

Hypochlorous Acid helps to avoid over-exfoliating or irritating the skin

A pragmatic perioperative counseling and risk-minimization framework is proposed for orthopaedic surgical patients reporting peptide exposure ( Figure 1 )

Eli Lilly is planning to submit orforglipron (Foundayo) for the treatment of T2DM in the second quarter of 2026 under the CNPV pilot program, making it possible for the drug to receive FDA approval in late 2026

doi: 10.1042/BJ20081386 50 HaschemiAKosmaPGilleLEvansCRBurantCFStarklPet al